Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) Net Income (QoQ) (2012 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) Net Income (QoQ) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -48.96%
Mar 31, 2026 -9.66%
Dec 31, 2025 35.78%
Sep 30, 2025 -1.82%
Jun 30, 2025 19.38%
Mar 31, 2025 -1.59%
Dec 31, 2024 22.14%
Sep 30, 2024 -26.36%
Jun 30, 2024 27.28%
Mar 31, 2024 6.74%
Dec 31, 2023 -18.86%
Sep 30, 2023 28.05%
Jun 30, 2023 -3.74%
Mar 31, 2023 -29.92%
Dec 31, 2022 -10.08%
Sep 30, 2022 16.93%
Jun 30, 2022 5.63%
Mar 31, 2022 -11.55%
Dec 31, 2021 -23.11%
Sep 30, 2021 -1.82%